AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders

Rhea-AI Summary

AtriCure, Inc. (NASDAQ: ATRC) announced an investor education webcast scheduled for September 28, 2022, at 2:00 p.m. ET, focusing on Hybrid AF Therapy. The webcast will feature insights from management and leading experts, alongside an interactive Q&A session. Interested participants can register on the company’s website. AtriCure is recognized for its innovative solutions addressing atrial fibrillation (Afib), with products such as the Isolator® Synergy™ Ablation System and AtriClip® LAA Exclusion System. These technologies cater to a market affecting over 33 million people globally.

Positive

• The Isolator® Synergy™ Ablation System is the first FDA-approved device for persistent Afib treatment.
• AtriCure's AtriClip® products are the most widely sold devices for left atrial appendage management globally.
• The upcoming webcast indicates active engagement with investors and provides a platform for education and interaction.

Negative

• None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy.

The webcast will include remarks from management and key opinion leaders, as well as an interactive question and answer session. Interested parties may register for access to a live webcast and slide presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com. A replay of the webcast will be available following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005551/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis or Marissa Bych

Gilmartin Group

Investor Relations

lynn@gilmartinir.com

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

What is the date and time of AtriCure's investor education webcast?

The investor education webcast will take place on September 28, 2022, at 2:00 p.m. ET.

What will be discussed in the AtriCure investor webcast?

The webcast will focus on Hybrid AF Therapy and feature remarks from management and key opinion leaders.

How can I register for the AtriCure investor webcast?

Interested parties can register by visiting the 'Investors' section of AtriCure's website.

What are AtriCure's key products for treating atrial fibrillation?

AtriCure's key products include the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.

How many people are affected by atrial fibrillation worldwide?

Atrial fibrillation affects over 33 million people worldwide.